최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0891592 (2010-09-27) |
등록번호 | US-8226558 (2012-07-24) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 4 인용 특허 : 1634 |
An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing
An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.
1. A glucose monitoring system comprising: a subcutaneous in vivo sensor for monitoring a glucose level of an interstitial fluid of a user;a sensor control unit coupled to the sensor to output one or more signals associated with the monitored glucose level of the interstitial fluid of the user; anda
1. A glucose monitoring system comprising: a subcutaneous in vivo sensor for monitoring a glucose level of an interstitial fluid of a user;a sensor control unit coupled to the sensor to output one or more signals associated with the monitored glucose level of the interstitial fluid of the user; anda receiver/display unit in communication with the sensor control unit and comprising: a receiver to receive the outputted one or more signals associated with the monitored glucose level of the interstitial fluid of the user from the sensor control unit;an input device to receive an input from the user, wherein the input comprises, a medication sensitivity, drug delivery information, a food intake, and an exercise level;a processor to evaluate the one or more signals received by the receiver to produce a first set of results comprising: (i) the glucose level in interstitial fluid of the user,(ii) a rate of change of the glucose level, and(iii) an acceleration in the rate of change of the glucose level,wherein the processor further evaluates the input from the user and the first set of results to determine a dose of a medication; anda display in communication with the processor. 2. The system of claim 1, wherein the medication comprises insulin. 3. The system of claim 1, wherein the display displays a warning indication to the user if one or more of the glucose level, the rate of change of the glucose level and the acceleration in the rate of change of the glucose level meets or exceeds a threshold level. 4. The system of claim 3, wherein the warning indication comprises one of more of: an indication of hypoglycemia; an indication of impending hypoglycemia; an indication of hyperglycemia; an indication of impending hyperglycemia; an indication of a malfunction; and an indication of an error condition. 5. The system of claim 1, wherein the processor tags the one or more signals with an event marker. 6. The system of claim 5, wherein the event marker comprises one or more of a hypoglycemic episode, a hyperglycemic episode, the food intake, the drug delivery information, and the exercise level. 7. The system of claim 1, wherein the system comprises an integrated unit including the sensor, the sensor control unit and the receiver/display unit. 8. The system of claim 1, wherein the sensor control unit and the receiver/display unit are separate units. 9. The system of claim 8, wherein the sensor control unit comprises a transmitter to transmit the one or more signals from the sensor control unit to the receiver/display unit. 10. The system of claim 1, wherein the receiver/display unit further comprises a data storage unit to store at least one of the one or more signals and the result. 11. The system of claim 1, wherein the receiver/display unit further comprises a port to connect the receiver/display unit to a computer. 12. The system of claim 11, wherein the receiver/display unit transmits at least one of the one or more signals and the result from the receiver/display unit to the computer. 13. The system of claim 1, wherein the display displays the result as a graph. 14. The system of claim 1, wherein the input device comprises a touch screen display. 15. The system of claim 1, wherein the sensor comprises an implantable glucose sensor. 16. The system of claim 1, further comprising a medication administration device. 17. The system of claim 16, wherein the medication administration device comprises at least one of a needle, a syringe, a pump, a catheter, an inhaler, or a transdermal patch. 18. A method of monitoring a glucose level of a user, the method comprising: monitoring a glucose level of a user with a subcutaneous in vivo sensor for monitoring the glucose level of an interstitial fluid of the user;outputting from a sensor control unit one or more signals associated with the monitored glucose level of the interstitial fluid of the user;receiving at a receiver/display unit the outputted one or more signals associated with the monitored glucose level of the interstitial fluid of the user;receiving an input from the user through an input device, wherein the input comprises a medication sensitivity, a drug delivery information, a food intake, and an exercise level;analyzing the one or more signals received by the receiver/display unit with a processor of the receiver/display unit to produce a first set of results comprising: (i) the glucose level in interstitial fluid of the user,(ii) a rate of change of the glucose level, and(iii) an acceleration in the rate of change of the glucose level;analyzing the input from the user and the first set of results with the processor to determine a dose of a medication; anddisplaying the glucose level of the user on a display of the receiver/display unit. 19. The method of claim 18, wherein the analyzing the one or more signals comprises one or more of: modifying the one or more outputted signals from the sensor control unit; determining the glucose level in interstitial fluid of the user; determining the rate of change of the glucose level; determining the acceleration in the rate of change of the glucose level; comparing one or more of the glucose level, the rate of change of the glucose level and the acceleration in the rate of change of the glucose level to a threshold value; evaluating trends in the glucose level over time; reducing noise; and reducing error. 20. The method of claim 18, wherein the medication comprises insulin. 21. The method of claim 18, further comprising displaying a warning indication to the user if one or more of the glucose level, the rate of change of the glucose level and the acceleration in the rate of change of the glucose level meets or exceeds a threshold value. 22. The method of claim 21, wherein the warning indication comprises one of more of: an indication of hypoglycemia; an indication of impending hypoglycemia; an indication of hyperglycemia; an indication of impending hyperglycemia; an indication of a malfunction; and an indication of an error condition. 23. The method of claim 18, further comprising tagging the one or more signals with an event marker. 24. The method of claim 23, wherein the event marker comprises one or more of a hypoglycemic episode, a hyperglycemic episode, the food intake, the drug delivery information, and the exercise level. 25. The method of claim 18, wherein the outputting comprises wirelessly transmitting the one or more signals from the sensor control unit to the receiver/display unit. 26. The method of claim 18, further comprising storing at least one of the one or more signals and the result in a data storage unit of the receiver/display unit. 27. The method of claim 18, further comprising connecting the receiver/display unit to a computer. 28. The method of claim 27, further comprising transmitting at least one of the one or more signals and the result from the receiver/display unit to the computer. 29. The method of claim 18, wherein the displaying comprises displaying the result as a graph. 30. The method of claim 18, wherein the input device comprises a touch screen display. 31. The method of claim 18, wherein the sensor comprises an implantable glucose sensor. 32. The method of claim 18, further comprising administering a dose of a medication to the user using a medication administration device. 33. The method of claim 32, wherein the medication administration device comprises at least one of a needle, a syringe, a pump, a catheter, an inhaler, or a transdermal patch. 34. A method of managing insulin therapy of a user, the method comprising: analyzing with a processor of a receiver/display unit one or more signals associated with a subcutaneous in vivo monitored glucose level of an interstitial fluid of the user to produce a first set of results comprising: (i) the glucose level in interstitial fluid of the user,(ii) a rate of change of the glucose level, and(iii) an acceleration in the rate of change of the glucose level;analyzing with the processor an input from the user and the first set of results, wherein the input comprises a drug delivery information, a food intake, and an exercise level, to determine a dose of insulin;displaying the dose of insulin to the user on a display of the receiver/display unit; andadministering the dose of insulin to the user using a medication administration device. 35. The method of claim 34, wherein the input from the user further comprises a medication sensitivity. 36. The method of claim 34, further comprising displaying a warning indication to the user if one or more of the glucose level, the rate of change of the glucose level and the acceleration in the rate of change of the glucose level meets or exceeds a threshold value. 37. The method of claim 36, wherein the warning indication comprises one of more of: an indication of hypoglycemia; an indication of impending hypoglycemia; an indication of hyperglycemia; an indication of impending hyperglycemia; an indication of a malfunction; and an indication of an error condition. 38. The method of claim 34, further comprising tagging the one or more signals with an event marker. 39. The method of claim 38, wherein the event marker comprises one or more of a hypoglycemic episode, a hyperglycemic episode, the food intake, the drug delivery information, and the exercise level. 40. The method of claim 34, further comprising storing the result in a data storage unit of the receiver/display unit. 41. The method of claim 34, further comprising connecting the receiver/display unit to a computer. 42. The method of claim 41, further comprising transmitting the result from the receiver/display unit to the computer. 43. The method of claim 34, wherein the displaying comprises displaying the result as a graph. 44. The method of claim 34, wherein the medication administration device comprises at least one of a needle, a syringe, pump, a catheter, an inhaler, or a transdermal patch.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.